M atrix metalloproteinases (MMPs) are a family of Ͼ20
enzymes that have long puzzled scientists for their diversity in tissue location and function. True to their name, MMPs are best known for their role as degradation enzymes cleaving multiple components of the extracellular matrix, including collagen, laminin, elastin, and fibronectin. However, the traditional view that MMPs are proteases whose only function is to target matrix proteins does not hold up anymore. A large body of evidence suggests that the proteolysis of extracellular matrix scaffold proteins causes release of growth factors and other bioactive molecules, indicating that MMPs are involved in the regulation of cell and tissue function. 1 Moreover, recent proteomic screens for MMP substrates have shown that MMPs regulate a host of signaling molecules, such as chemokines, both directly and indirectly. 2 The novel functions of MMPs are also crucial to the cardiovascular system. MMP enzymes can regulate, for instance, the bioavailability of vascular endothelial growth factor and the potent vasodilator adrenomedullin. 2 The diverse roles of MMPs are relevant not only for physiological processes such as heart development but also for pathological processes such as remodeling events resulting from myocardial infarction, hypertensive heart disease, or cardiomyopathy. 3
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Importantly, members of the MMP family can also have intracellular localizations: MMP-2, which is abundantly expressed in cardiac cells, is found in organelles like the nucleus and the mitochondria, as well as at the caveolae and the cytoskeleton and in particular at the sarcomeres (Figure) . 4 The sarcomeric localization was shown to be mediated by MMP-2 binding to troponin-I, 5 ␣-actinin, 6 and myosin light chain-1. 7 In this series of studies, Schulz and coworkers 4 established that the 3 sarcomeric proteins are degraded by MMP-2 after activation of the protease during ischemia/reperfusion (I/R) damage, thus contributing to acute contractile dysfunction under oxidative stress. The same laboratory now provides evidence in this issue that the giant protein titin, a structural, elastic, and signaling molecule spanning half of the sarcomere, is a novel target of MMP-2 and is also degraded during I/R injury ( Figure) . 8
Titin Functions and Alterations in Human Heart Disease
Titin, the largest protein of the human body, has multiple important functions in the heart, providing both a scaffold for myofibril assembly and a hub for various molecules participating in myocyte signaling pathways. 9,10 Perhaps best known is the role of titin as an elastic spring contributing to total myocardial passive (diastolic) stiffness. The titin springs located in the I-band segment of the sarcomere ( Figure) are the predominant source of myocardial passive stiffness in the normal human heart, even exceeding the contribution to stiffness coming from the collagen fibers of the extracellular matrix. 11 In end-stage failing hearts of patients with dilated cardiomyopathy, the contribution of titin to total myocardial passive stiffness decreases, whereas the contribution made by collagen increases. 11 Moreover, cardiac titin is expressed in 2 main isoforms: the shorter and stiffer N2B isoform and the longer, more compliant, N2BA isoform (which, in fact, has multiple splice pathways). Importantly, the N2BA:N2B isoform ratio is increased in end-stage failing human hearts compared with donor hearts in both chronically ischemic hearts of patients with coronary artery disease 12 and nonischemic dilated cardiomyopathy hearts. 11, 13 The titin-isoform switch decreases passive myocyte stiffness, probably as a compensatory mechanism counteracting an increased total passive stiffness related to fibrosis. 10 Dysregulation of titin stiffness in cardiac failure could severely impair various mechanical functions of the heart, including diastolic filling and early diastolic recoil, for which titin is held partially responsible, 9 length-dependent activation as the molecular basis of the Frank-Starling mechanism, 9 and contractile performance in systole, which is supported by the titin springs. 10 Other alterations to cardiac titin occur in heart disease, such as reduced levels of protein kinase A-or protein kinase G-mediated titin phosphorylation, observed in human dilated cardiomyopathy hearts. 14, 15 This titin phosphorylation deficit in end-stage failing hearts increases myocyte passive stiffness and contributes to impaired diastolic function. Furthermore, cardiac-specific regions in titin are vulnerable to intramolecular disulfide bonding, which could stiffen the titin springs under oxidative stress conditions. 16 These recent findings complement earlier studies of ischemic and failing human hearts, which showed that titin is degraded 17 and appears highly disorganized in the cardiomyocytes when analyzed by immunofluorescence microscopy. 18 Taken together, evidence for titin alterations in human heart disease is manifold; derangement of titin in cardiac myocytes and reduced titin expression are obvious.
Proteases Targeting Cardiac Titin
Little has been known about specific proteases targeting cardiac titin in acute or chronic myocardial dysfunction. On the other hand, titin is notorious for rapid degradation ex vivo: Protease inhibitors are required to keep titin intact. 12 A curious correlation has been found between the extent of titin-isoform transitions in chronic ischemic human heart disease and the degree of cardiac troponin-I degradation or complex formation. 12 A candidate enzyme potentially degrading titin is the ubiquitous Ca 2ϩdependent protease calpain-1, which has been implicated in the pathogenesis of myocardial dysfunction after I/R. Indeed, calpain-1 binds titin near the Z-disk 19 and in vitro degrades various cytoskeletal and myofibrillar proteins isolated from human cardiac tissue, including titin. 20 Titin is also proteolyzed in cultured rat cardiomyocytes after doxorubicin treatment to induce calpain-1. 21 Similar to calpain-1, MMP-2 targets a subset of structural and regulatory sarcomeric proteins, including titin (Figure) .
The important news is that MMP-2 is activated by oxidative stress after I/R and degrades titin both in an ex vivo working rat heart model of I/R and in an in vivo mouse model of I/R. 8 However, it remains to be answered unambiguously whether the degradation of titin and other intracellular target proteins under oxidative stress in vivo is due mainly to the activity of MMP-2 or calpain-1 or both. The authors address this issue by showing reduced titin degradation in hearts from MMP-2 knockout mice subjected to I/R in vivo, suggesting that MMP-2 really does the job, at least in part. 8 Along the same line, titin cleavage induced by I/R damage was diminished by an MMP inhibitor. In summary, in light of the importance of titin for diastolic and systolic function, titin degradation by MMP-2 (and perhaps calpain-1) likely contributes to the acute contractile depression developing in stunned myocardium.
Figure.
Diversity in cellular location and function of matrix metalloproteinase-2 (MMP-2), emphasizing the novel binding and cleavage target titin. Oxidative stress, evoked by I/R injury, generates peroxynitrite (ONOO Ϫ ), which activates MMP-2. The MMP is found, among others, in the nucleus and mitochondria and at the cytoskeleton and caveolae. In the sarcomeres, activated MMP-2 degrades troponin-I (TnI) on the thin filaments, myosin light chain-1 (MLC-1) on the thick filaments, ␣-actinin in the Z-disk, and titin. MMP-2 binding to titin may preferentially occur near the Z-disk, whereas cleavage of titin could take place at multiple sites in the Z-disk, I-band, A-band, and M-band portions. Titin cleavage by MMP-2 might add to the acute myocardial contractile dysfunction in I/R. MMP-2 can also trigger signaling events leading to either necrosis or apoptosis. In the extracellular compartment, MMP-2 can be activated by proteolytic cleavage.
Activation of MMP-2 During I/R Injury
The intracellular activation of MMP-2 as an effector of acute myocardial I/R injury in cardiomyocytes occurs via generation of peroxynitrite, a highly pro-oxidant species that increases to cardiotoxic levels within the first minutes of I/R. 4 Peroxynitrite activates cytosolic MMP-2 from an inactive precursor state, and MMP-2 now executes its actions on the sarcomeric proteins, troponin-I, myosin light chain-1, ␣-actinin, and titin (Figure) . Ali et al 8 propose that MMP-2 binding to titin occurs preferentially near the Z-disk, as suggested by colocalization of immunofluorescence signals for MMP-2 and Z-disk-adjacent titin antibodies. However, the MMP-2 binding site(s) on titin still need to be mapped precisely. Whether the binding sites on titin are also the sites of titin cleavage is another open question. From sequence analysis, the authors predict potential cleavage sites in various regions along the titin filament, including the Z-disk-flanking, I-band, and A-band segments (Figure) . Providing experimental evidence in support of these predictions could be a challenging task, given the huge size (3000 to 4000 kDa) of the titin molecule.
Despite convincing evidence showing that MMP-2 degrades titin, it is not clear whether this cleavage, or even that of other sarcomeric proteins, is the principal cause of reduced cardiac work output during I/R injury. More likely, the contractile depression after oxidative stress has additional causes. MMP-2 by itself probably has biological actions in other subcellular compartments, such as caveolae, mitochondria, and the nucleus, as well as in the extracellular space (Figure) . The nature of these actions is still largely unknown, but both acute and long-term effects on contractile performance triggered by I/R damage could originate here. Finally, MMP-2 has links to signaling molecules associated with the development of apoptosis or necrosis, and it has been discussed that higher levels of oxidative stress could preferentially induce these pathways, causing irreversible cell injury. 4
Conclusion
The article by Ali et al 8 is important because it demonstrates for the first time an acute effect of a protease, MMP-2, on the stability of the giant elastic protein titin as a consequence of oxidative stress during I/R. The finding provides another piece of evidence for an intracellular role of MMP-2. The study also uncovers a previously unrecognized link between the 2 components principally responsible for myocardial passive stiffness: extracellular matrix proteins ("classically" degraded by MMPs) and titin filaments. Both components are remodeled in heart disease, with detrimental effects on cardiac performance. Inhibiting MMP-2 activity by pharmacological intervention could be a desirable cardioprotective strategy in I/R injury and possibly also in chronic heart failure.
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